Advertisement

ß-Adrenerge Signaltransduktion am insuffizienten menschlichen Herzen

  • M. Böhm
Chapter

Zusammenfassung

Die WHO hat das Syndrom Herzinsuffizienz im Jahr 1996 als einen Symptomenkomplex mit typischen Symptomen wie einer Abnahme der körperlichen Leistungsbereitschaft (klinische Definition) aufgrund einer linksventrikulären Funktionsstorung (pathophysiologische Definition) definiert. Da unter körperlicher Belastung die Anpassung der Herzauswurfleistung durch eine vermehrte Aktivität des sympathischen Nervensystems oder eine Stimulation des Herzens mit Katecholaminen vermittelt wird, erklärt sich daraus, daß eine Dysregulation des sympathischen Nervensystems einen wesentlichen Beitrag zur Pathophysiologic der Herzinsuffizienz leistet. Seit Jahren ist bekannt, daß das sympathische Nervensystem bei Herzinsuffizienz aktiviert ist [1]. Dies zeigt sich in einer Erhöhung der zirkulierenden Noradrenalinplasmakonzentrationen, deren Höhe eine enge Korrelation zur Prognose der Herzinsuffizienz aufweist [2]. Diese präsynaptische Aktivierung hat wiederum bei längerem Bestehen wichtige Konsequenzen fur die präsynaptische und postsynaptische Regulation der myokardialen Kontraktilität durch das sympathische Nervensystem.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Packer M (1988) Neurohormonal interactions and adaptations in congestive heart failure. Circulation 77: 721–730.PubMedCrossRefGoogle Scholar
  2. 2.
    Cohn JN, Levine TB, Olivari MT et al. (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823.PubMedCrossRefGoogle Scholar
  3. 3.
    Gille E, Lemoine H, Ehle B, Kaumann AJ (1985) The affinity of (-)-propranolol for β1- and β2- receptors of human hearts. Differential antagonism of the positive inotropic effects and adenylate cyclase stimulation by (-)-noradrenaline and (-)-adrenaline. Naunyn Schmiedebergs Arch Pharmacol 331: 60–70.PubMedCrossRefGoogle Scholar
  4. 4.
    Lohse MJ (1992) Mechanisms of β-adrenergic receptor desensitization. In: Hargave PA, Hof- mann KP, Kaupp UB (eds) Signal transmission in photoreceptor systems. Springer, Berlin Heidelberg New York Tokyo, pp 160–171.Google Scholar
  5. 5.
    Hausdorff WP, Caron MG, Lefkowitz RJ (1990) Turning off the signal: Desensitization of P-adrenergic receptor function. FASEB J 4: 2881–2889.PubMedGoogle Scholar
  6. 6.
    Lohse MJ, Benovic JL, Codina J, Caron MG, Lefkowitz RJ (1990) β-Arrestin: A protein that regulates p-adrenergic receptor function. Science 248: 1547–155s0.PubMedCrossRefGoogle Scholar
  7. 7.
    Lohse MJ, Benovic JL, Caron MG, Lefkowitz RJ (1990) Multiple pathways of rapid β2-adrener- gic receptor densitization. J Biol Chem 265: 3202–3209.PubMedGoogle Scholar
  8. 8.
    Hadcock JR, Malbon CC (1991) Regulation of receptor expression by agonists: Transcriptional and posttranscriptional controls. Trends Neurosci 14: 242–247.PubMedCrossRefGoogle Scholar
  9. 9.
    Swedberg K, Viquerat C, Rouleau JL, Roizen M, Atherton B, Parmley WW, Chatterjee K (1984) Comparison of myocardial catecholamine balance in chronic congestive heart failure and in angina pectoris without failure. Am J Cardiol 54: 783–789.PubMedCrossRefGoogle Scholar
  10. 10.
    Kaye DM, Lefkovitz J, Jennings GL, Bergin P, Broughton A, Esler MD (1995) Adverse consequences of high sympathetic nervous activity in the failing human heart. J Am Coll Cardiol 26: 1257–1263.PubMedCrossRefGoogle Scholar
  11. 11.
    Bristow MR, Anderson FL, Port DP et al. (1991) Differences in β-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 84: 1024–1039.PubMedGoogle Scholar
  12. 12.
    Böhm M, La Rosee K, Schwinger RHG, Erdmann E (1995) Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol 25: 146–153.PubMedCrossRefGoogle Scholar
  13. 13.
    Bristow MR, Ginsburg R, Minobe W et al. (1982) Decreased catecholamine sensitivity and p-adrenergic receptor density in failing human hearts. N Engl J Med 307: 205–211.PubMedCrossRefGoogle Scholar
  14. 14.
    Brodde OE (1991) β1- and β2-Adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203–242.PubMedGoogle Scholar
  15. 15.
    Steinfath M, Geertz B, Schmitz W et al. (1991) Distinct downregulation of cardiac β1- and β2- adrenoceptors in different human heart diseases. Naunyn Schmiedebergs Arch Pharmacol 343: 217–220.PubMedCrossRefGoogle Scholar
  16. 16.
    Bristow MR, Hershberger RE, Port JD, Minobe W, Rasmussen R (1989) β1- and β2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing. and failing human ventricular myocardium. Mol Pharmacol 35: 295–303.PubMedGoogle Scholar
  17. 17.
    Ungerer M, Böhm M, Elce JS, Erdmann E, Lohse MJ (1993) Altered expression of β-adrenergic receptor kinase and p-adrenergic receptors in the failing human heart. Circulation 87: 454–463.PubMedGoogle Scholar
  18. 18.
    Bristow ME, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, Feldmann AM (1993) Reduced β1-receptor messenger RNA abundance in the failing human heart. J Clin Invest92: 2737–2745.PubMedCrossRefGoogle Scholar
  19. 19.
    Ihl-Vahl R, Eschenhagen T, Kiibler W et al. (1996) Differential regulation of mRNA specific for β1- and β2-adrenergic receptors in human failing hearts. Evaluation of the absolute cardiac mRNA levels by two independent methods. J Mol Cell Cardiol 28: 1–10.Google Scholar
  20. 20.
    Ungerer M, Parruti G, Bohm M, Puzicha M, DeBlase A, Erdmann E, Lohse MJ (1994) Expression of β-arrestins and P-adrenergic receptor kinases in the failing human heart. Circ Res 74: 206–213.PubMedGoogle Scholar
  21. 21.
    Böhm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold C, Erdmann E (1988) Subsensiti- vity of the failing human heart to isoprenaline and milrinone is related to β-adrenoceptor downregulation. J Cardiovasc Pharmacol 12: 726–732.PubMedCrossRefGoogle Scholar
  22. 22.
    Böhm M, Beuckelmann D, Brown L et al. (1988) Reduction of β-adrenoceptor density and evaluation of positive inotropic responses in isolated, diseased human myocardium. Eur Heart J 9: 844–852.PubMedGoogle Scholar
  23. 23.
    Böhm M, Morano I, Pieske B, Riiegg JC, Wankerl M, Zimmermann R, Erdmann E (1991) Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 68: 689–701.PubMedGoogle Scholar
  24. 24.
    Moss J, Vaughan M (1988) ADP-ribosylation of guanyl nucleotide-binding regulatory proteins by bacterial toxins. Adv Enzymol 61: 13303–13379.Google Scholar
  25. 25.
    Insel PA, Ransnäs LA (1988) G proteins and cardiovascular disease. Circulation 78: 1511–1513.PubMedCrossRefGoogle Scholar
  26. 27.
    Schnabel P, Böhm M, Gierschik P, Jakobs KH, Erdmann E (1990) Improvement of cholera toxin-catalyzed ADP-ribosylation by endogenous ADP-ribosylation factor from bovine brain provides evidence for an unchanged amount of Gsa in failing human myocardium. J Mol Cell Cardiol 22: 73–82.PubMedCrossRefGoogle Scholar
  27. 28.
    Feldman AM, Cates AE, Veazey WB et al. (1988) Increase in the 40,000-mol wt pertussis toxin substrate (G-protein) in the failing human heart. J Clin Invest 82: 189–197.PubMedCrossRefGoogle Scholar
  28. 29.
    Milligan G (1988) Techniques used in the identification and analysis of function of pertussis toxin-sensitive guanine nucleotide binding proteins. Biochem J 255: 1–13.PubMedGoogle Scholar
  29. 30.
    Glman AG (1987) G proteins: Transducers of receptor-generated signals. Ann Rev Biochem 56: 615–649.CrossRefGoogle Scholar
  30. 31.
    Böhm M, Eschenhagen T, Gierschik P et al. (1994) Radioimmunochemical quantification of Gia in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol 26: 133–149.PubMedCrossRefGoogle Scholar
  31. 32.
    Hershberger RE, Feldman AM, Bristow MR (1991) Al-Adenosine receptor inhibition of adenylate cyclase in failing and nonfailing human ventricular myocardium. Circulation 83: 1343–1351.PubMedGoogle Scholar
  32. 33.
    Böhm M, Gierschik P, Jakobs KH, Pieske B, Schnabel P, Ungerer M, Erdmann E (1990) Increase of Gia in human hearts with dilated but not ischemic cardiomyopathy. Circulation 82: 1249–1265.PubMedCrossRefGoogle Scholar
  33. 34.
    Neumann J, Scholz H, Döring V, Schmitz W, v. Meyerinck L, Kalmar P (1988) Increase in myocardial Gi-proteins in heart failure. Lancet II: 936–937.CrossRefGoogle Scholar
  34. 35.
    Eschenhagen T, Mende U, Nose M et al. (1992) Increased messenger RNA level of the inhibitory G-protein a-subunits Gia2 in human end-stage heart failure. Circ Res 70: 688–696.PubMedGoogle Scholar
  35. 36.
    Müller FU, Boheler KR, Eschenhagen T, Schmitz W, Scholz H (1993) Isoprenaline stimulates gene transcription of the inhibitory G protein a-subunit Gia2 in rat heart. Circ Res 72: 696–700.PubMedGoogle Scholar
  36. 37.
    Böhm M, Kirchmayr R, Gierschik P, Erdmann E (1995) Increase of myocardial inhibitory G-proteins in catecholamine-refractory septic shock or in septic multiorgan failure. Am J Med 98: 183–186.PubMedCrossRefGoogle Scholar
  37. 38.
    Brown LA, Harding SE (1992) The effect of pertussis toxin on β-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure. Br J Pharmacol 106: 115–122.PubMedGoogle Scholar
  38. 39.
    Böhm M, Ungerer M, Erdmann E (1993) Adenosine receptors in the human heart: pharmacological characterization in nondiseased and cardiomyopathic tissue. Drug Develop Res 28: 268–276.CrossRefGoogle Scholar
  39. 40.
    Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A (1989) Long-term β-blockade in dilated cardiomyopathy: effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 80: 551–563.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • M. Böhm

There are no affiliations available

Personalised recommendations